To date, PRPF19 has not been studied in ovarian cancer; however, these previous studies imply that the gain of PRPF19 is a critical event during the progression of cancer, making it a promising target for malignancies with aberrant PRPF19 expression. This evidence concerns the gene PRPF19 and ovarian carcinoma.